EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSLOCG00000002439
Gene Symbol: PSMD13
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSLOCG00000008596
Gene Symbol: PSMD14
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSLOCG00000008710
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSLOCG00000010311
Gene Symbol: PSMD6
3 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSLOCG00000003971
Gene Symbol: PSMD7
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSLOCG00000014197
Gene Symbol: PSMD8
1 Cross references
211 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSLOCG00000000250
Gene Symbol: LOC102683700
2 Cross references
219 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSLOCG00000012412
Gene Symbol: LOC102684798
3 Cross references
210 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSLOCG00000013639
Gene Symbol: PRKCA
3 Cross references
290 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSLOCG00000014468
Gene Symbol: PRKCD
3 Cross references
280 Possible Orthologues:

Protein Kinase C Epsilon

Ensembl ID : ENSLOCG00000016351
Gene Symbol: PRKCE
3 Cross references
342 Possible Orthologues:

Protein Kinase C Iota

Ensembl ID : ENSLOCG00000007237
Gene Symbol: PRKCI
3 Cross references
87 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).